Search results

In a tight market for primary venture fundraising, a historically high number of startups are turning to bridge rounds.

IPOs are the lifeblood of venture capital, but they've been few and far between in recent years. Investors are watching to see if the success of some recent high-profile listings will provide a much-needed spark.

Health and biotech VC fundraising surged in the aftermath of the COVID-19 pandemic and has stood strong against market headwinds.

After two-plus years of steady declines, the Series C market may be bouncing back.

These days, investors have more leverage than startups in deal negotiations. How are they choosing to use it?

The geographic diversification of VC has been a developing trend in recent years. Q1 2024 showed a possible reversal.

At Series D and later, VC deal activity slowed down in Q1 2024. There are reasons for the decline on both sides of the negotiating table.

In a new-look venture climate, stock options and other types of company equity might be losing some of their luster in the eyes of employees.

The median venture round size increased at every stage from seed to Series C during Q1 2024, a welcome development for cash-hungry startups.

An increasing number of seed-stage rounds are extension financings, or bridge rounds.

Median seed valuations trended up in Q4 in the healthtech, consumer, and fintech sectors. In other key metrics, the numbers weren’t so rosy.